Research programme: antiviral compounds - Roche/Gilead

Drug Profile

Research programme: antiviral compounds - Roche/Gilead

Alternative Names: Antiviral compounds research programme - Roche/Gilead; CDK inhibitors research programme - Roche/Gilead; Cyclin-dependent kinase inhibitors research programme - Roche/Gilead

Latest Information Update: 21 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gilead Sciences
  • Developer Anadys Pharmaceuticals; Gilead Sciences
  • Class
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Viral infections

Most Recent Events

  • 19 Jun 2006 No development reported - Preclinical for Viral infections in USA (unspecified route)
  • 20 Feb 2004 Data presented at the 11th Conference on Retroviruses and Opportunistic Infections (CROI-2004) have been added to the Viral infections pharmacodynamics section
  • 19 Jun 2002 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top